AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30690294 — intervention group
Group type: EXPERIMENTAL
Intervention: trametinib (2 mg orally, once daily; n = 214)
Number of subjects: 322
Study 30690294 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy (dacarbazine [1000 mg/m2] or paclitaxel [175 mg/m2] intravenously, every 3 weeks; n = 108)
Number of subjects: 322
Study 30690294 — intervention group
Group type: EXPERIMENTAL
Intervention: trametinib
Number of subjects: 322
Study 30690294 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 322
Study 30527176 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiated postoperative rehabilitation (14 days after surgery)
Number of subjects: 235
Study 30527176 — intervention group
Group type: COMPARATOR
Intervention: Late initiated postoperative rehabilitation (14 weeks after surgery)
Number of subjects: 235
Study 27433858 — intervention group
Group type: COMPARATOR
Intervention: Observation arm (no intervention)
Number of subjects: 80
Study 25295436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 40 minutes)
Number of subjects: 26
Study 22852054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat Meal + Maltodextrin (HFM + M)
Number of subjects: 0
Study 22852054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat Meal + Placebo (HFM + P)
Number of subjects: 0
Study 22852054 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate Meal + Placebo (HCM + P)
Number of subjects: 0
Study 20369312 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin zeta
Number of subjects: 462
Study 20369312 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 462
Study 17646492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentures-In group (ventilated with dentures in place)
Number of subjects: 166
Study 17646492 — intervention group
Group type: COMPARATOR
Intervention: Dentures-Out group (ventilated with dentures removed)
Number of subjects: 166
Study 16098604 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuG-CSF (5 microg/kg daily for 3 weeks)
Number of subjects: 12
Study 16098604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 12
Study 12402720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms kg‐1 infusion over 20 min, PCA clonidine 20 micrograms and morphine 1 mg bolus
Number of subjects: 60
Study 12402720 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion and PCA morphine 1 mg bolus
Number of subjects: 60
Study 10363933 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over the visual cortex
Number of subjects: 0
Study 8646021 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation for three months
Number of subjects: 151
Study 8646021 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three months
Number of subjects: 151
Study 1384117 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (5 g at hours 0, 12, 24, 36 and 2 x 3 g on days 3 to 7 by intravenous infusion over 2 hours)
Number of subjects: 20
Study 1384117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6535339 — intervention group
Group type: COMPARATOR
Intervention: Discontinue medication with no dietary intervention
Number of subjects: 0
Study 6535339 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue medication and reduce weight
Number of subjects: 0
Study 6535339 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue medication and reduce sodium
Number of subjects: 0
Study 6535339 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue medication
Number of subjects: 0
Study 30665671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (20mL 0.5%)
Number of subjects: 93
Study 30665671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (20mL 0.5%) + Dexmedetomidine (1mL, 100μg)
Number of subjects: 93
Study 30665671 — intervention group
Group type: COMPARATOR
Intervention: Control (Post-operative i.v. morphine via patient‐controlled analgesia without paravertebral blockade)
Number of subjects: 93
Study 29571953 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate (0.4 mg)
Number of subjects: 40
Study 29571953 — intervention group
Group type: COMPARATOR
Intervention: Control injection of sterile saline water
Number of subjects: 40
Study 25911092 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized behavioral intervention
Number of subjects: 152
Study 25060083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scan within 3-5 days (n=12)
Number of subjects: 27
Study 25060083 — intervention group
Group type: COMPARATOR
Intervention: Traditional diagnosis (radiographs 10-14 days postinjury; n=15)
Number of subjects: 27
Study 25060083 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 27
Study 25060083 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier survival analysis
Number of subjects: 27
Study 23005030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric Bayesian approach to estimate natural direct and indirect effects through a mediator
Number of subjects: 0
Study 23005030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity parameters elicitation strategies
Number of subjects: 0
Study 23005030 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach applied to mediation assessment
Number of subjects: 0
Study 18817993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for initial 14 days after PCI and subsequent 30 mg/day during 6-month follow-up
Number of subjects: 26
Study 18817993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study 17393542 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold depression in PD patients with dementia
Number of subjects: 538
Study 17393542 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients with subthreshold depression
Number of subjects: 538
Study 17393542 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 538
Study 16216739 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision and drainage
Number of subjects: 45
Study 16216739 — intervention group
Group type: COMPARATOR
Intervention: Needle aspiration
Number of subjects: 45
Study 12392123 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (diagnostic model based on symptoms and gynaecological examination)
Number of subjects: 204
Study 12392123 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (diagnostic model for identifying complete miscarriages)
Number of subjects: 204
Study 12392123 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner clinical judgement
Number of subjects: 204
Study 10433310 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid infusion of 100 mg/kg methotrexate (MTX) over 3 hours
Number of subjects: 29
Study 10433310 — intervention group
Group type: COMPARATOR
Intervention: Regular infusion of 100 mg/kg methotrexate (MTX) over 6 hours
Number of subjects: 29
Study 10433310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rapid and regular infusion followed by irradiation
Number of subjects: 29
Study 7776853 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU lymphoblastoid interferon
Number of subjects: 60
Study 7776853 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MU lymphoblastoid interferon
Number of subjects: 60
Study 7776853 — intervention group
Group type: COMPARATOR
Intervention: Both doses (3 MU and 6 MU)
Number of subjects: 60
Study 2323312 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral naltrexone
Number of subjects: 15
Study 2323312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous naloxone
Number of subjects: 15
Study 2323312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 662080 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (4 mg)
Number of subjects: 34
Study 662080 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide (3 mg)
Number of subjects: 34
Study 662080 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 34
Study 662080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (1 mg every 6 h for 7 days) followed by Metergoline
Number of subjects: 34
Study 662080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (1 mg every 6 h for 7 days) followed by Methysergide
Number of subjects: 34
Study 31930993 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor at 39 weeks
Number of subjects: 6096
Study 31930993 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 6096
Study 31148146 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient TLH (same-day discharge)
Number of subjects: 204
Study 31148146 — intervention group
Group type: COMPARATOR
Intervention: Inpatient TLH (overnight stay)
Number of subjects: 204
Study 27480385 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated asparaginase (PEG-ASP) 1000 IU/m2 administered on days 4 and 18 as part of a five-drug induction regimen
Number of subjects: 90
Study 27480385 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-ASP
Number of subjects: 90
Study 26143022 — intervention group
Group type: EXPERIMENTAL
Intervention: synchronized Transcranial Magnetic Stimulation (sTMS)
Number of subjects: 202
Study 26143022 — intervention group
Group type: COMPARATOR
Intervention: sham treatment
Number of subjects: 202
Study 26143022 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment-naïve subjects
Number of subjects: 202
Study 22889694 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS‐MPH)
Number of subjects: 299
Study 22889694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 21071617 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural and temporally reordered musical stimuli
Number of subjects: 20
Study 21071617 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural and temporally reordered speech stimuli
Number of subjects: 20
Study 21071617 — intervention group
Group type: COMPARATOR
Intervention: Heart rate variability and mean respiration rates
Number of subjects: 20
Study 21071617 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal structure manipulation
Number of subjects: 20
Study 18595749 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of intrathecal baclofen (CITB group)
Number of subjects: 17
Study 18595749 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (Control group)
Number of subjects: 17
Study 17090232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.3 mg.kg(‐1)
Number of subjects: 35
Study 17090232 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide 30% in oxygen
Number of subjects: 35
Study 17090232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 35
Study 14687010 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy for 8 weeks (group 1)
Number of subjects: 50
Study 14687010 — intervention group
Group type: COMPARATOR
Intervention: Observation for 8 weeks followed by standardized physiotherapy (group 2)
Number of subjects: 50
Study 14687010 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy
Number of subjects: 50
Study 11726429 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70
Study 11726429 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 70
Study 9175978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg-1
Number of subjects: 30
Study 9175978 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 7681289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch with high C2/C6-substitution ratio (10.8)
Number of subjects: 6
Study 7681289 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch with low C2/C6-substitution ratio (5.8)
Number of subjects: 6
Study 3632163 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM clinical intervention in the ED
Number of subjects: 72
Study 3632163 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM telephone call two days after the ED visit
Number of subjects: 72
Study 3632163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination clinical plus telephone intervention
Number of subjects: 72
Study 3632163 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 31939996 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) LVAD
Number of subjects: 1020
Study 31939996 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II (HMII) LVAD
Number of subjects: 1020
Study 29974637 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 nmol kg‐1 h‐1 kisspeptin
Number of subjects: 15
Study 29974637 — intervention group
Group type: COMPARATOR
Intervention: Vehicle administration
Number of subjects: 15
Study 27146116 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging program combined with nicotine patches and gum, quitline referral, and SmokefreeTXT enrollment (4 weeks duration)
Number of subjects: 60
Study 27146116 — intervention group
Group type: COMPARATOR
Intervention: Control group received a brochure describing the state smokers' quitline
Number of subjects: 60
Study 25603802 — intervention group
Group type: EXPERIMENTAL
Intervention: MGuard stent
Number of subjects: 50
Study 25603802 — intervention group
Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 50
Study 24074710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule (1.5 g, 3 times/day) with continued oral NAs (one tablet, 1 time/day) for 48 weeks
Number of subjects: 110
Study 24074710 — intervention group
Group type: COMPARATOR
Intervention: Nucleos(t)ide analogs only for 48 weeks
Number of subjects: 110
Study 20509823 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g fibre (fructose-oligosaccharides) diet supplementation
Number of subjects: 12
Study 20509823 — intervention group
Group type: COMPARATOR
Intervention: No fibre diet supplementation (control)
Number of subjects: 12
Study 18417246 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based combination chemotherapy (3 chemotherapy courses)
Number of subjects: 123
Study 15629418 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation for Pain Management Intervention (2 sessions including assessment and feedback based on the PPMP)
Number of subjects: 78
Study 15629418 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual and attention placebo interview)
Number of subjects: 78
Study 12907818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl‐Meyer arm scores of 11 points in the second week increasing to 19 points in the fourth week
Number of subjects: 102
Study 12907818 — intervention group
Group type: EXPERIMENTAL
Intervention: Motricity Index leg scores of at least 25 points in the first week
Number of subjects: 102
Study 12907818 — intervention group
Group type: EXPERIMENTAL
Intervention: Total anterior circulation infarcts, right hemisphere strokes, homonymous hemianopia, visual gaze deficit, visual inattention, and paresis
Number of subjects: 102
Study 12907818 — intervention group
Group type: EXPERIMENTAL
Intervention: Some dexterity in the paretic arm
Number of subjects: 102
Study 12907818 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete functional recovery
Number of subjects: 102
Study 12907818 — intervention group
Group type: EXPERIMENTAL
Intervention: No change in probabilities of prediction dexterity after 4 weeks
Number of subjects: 102
Study 10751373 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention focusing on the uncontrollability of weight
Number of subjects: 74
Study 10751373 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 8892458 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 302
Study 8892458 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 302
Study 8892458 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 302
Study 1993963 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 0.5 mg/kg every 6 hours for a total of six doses, starting 6 to 12 hours before extubation.
Number of subjects: 153
Study 1993963 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo).
Number of subjects: 153
Study 6388012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.d.)
Number of subjects: 9
Study 6388012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30632410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Atropine with Orthokeratology (AOK)
Number of subjects: 64
Study 30632410 — intervention group
Group type: COMPARATOR
Intervention: Ortho-k alone (OK)
Number of subjects: 64
Study 27177957 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag extraction (study group, 76 patients)
Number of subjects: 156
Study 27177957 — intervention group
Group type: COMPARATOR
Intervention: Standard extraction without bag (control group, 80 patients)
Number of subjects: 156
Study 26480304 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizers containing formaldehyde (concentrations > 40, 20-40, 2.5-10 p.p.m.)
Number of subjects: 15
Study 26480304 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizers without formaldehyde
Number of subjects: 15
Study 26480304 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without contact allergy to formaldehyde)
Number of subjects: 15
Study 25140822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Pedagogy (manipulation of task constraints including equipment and rules)
Number of subjects: 24
Study 25140822 — intervention group
Group type: COMPARATOR
Intervention: Linear Pedagogy (prescriptive, repetitive drills)
Number of subjects: 24
Study 23044180 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Technology (POCT) analysis
Number of subjects: 319
Study 23044180 — intervention group
Group type: COMPARATOR
Intervention: Tube transporting for central laboratory analyses
Number of subjects: 319
Study 18790598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine 10mg twice daily
Number of subjects: 50
Study 18790598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17883739 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 119
Study 17883739 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine with 2.5 microg/mL fentanyl
Number of subjects: 119
Study 17883739 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 119
Study 17883739 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine
Number of subjects: 119
Study 16087911 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (900 mg)
Number of subjects: 0
Study 16087911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12065457 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone-enanthate (NET-EN) 200 mg, single intramuscular injection
Number of subjects: 42
Study 12065457 — intervention group
Group type: COMPARATOR
Intervention: Testosterone undecanoate (TU) 1000 mg, four injections every 6 weeks plus daily oral placebo
Number of subjects: 42
Study 12065457 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg, four injections every 6 weeks plus daily oral levonorgestrel (LNG, 250 microg)
Number of subjects: 42
Study 12065457 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone-enanthate (NET-EN), four injections every 6 weeks
Number of subjects: 42
Study 10408822 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 34
Study 10408822 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 34
Study 7747232 — intervention group
Group type: EXPERIMENTAL
Intervention: Light normal activity intervention
Number of subjects: 975
Study 7747232 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional medical treatment)
Number of subjects: 975
Study 2291877 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 6140 (1200 mg single oral dose) after food intake
Number of subjects: 11
Study 2291877 — intervention group
Group type: COMPARATOR
Intervention: CGP 6140 (1200 mg single oral dose) after an overnight fast
Number of subjects: 11
Study 6271000 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g citrus pectin added to a mixed low fiber diet
Number of subjects: 8
Study 31049873 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program delivered by pharmacists during three 30-min interviews over a 6-month period.
Number of subjects: 377
Study 31049873 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 377
Study 28719262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone microscope
Number of subjects: 60
Study 27301301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment for 60 seconds
Number of subjects: 138
Study 27301301 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 138
Study 24854218 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 98
Study 24854218 — intervention group
Group type: COMPARATOR
Intervention: Intensive treatment-as-usual (TAU)
Number of subjects: 98
Study 23175199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 93
Study 23175199 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 93
Study 19279381 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB phototherapy combined with efalizumab (1 mg/kg body weight/week)
Number of subjects: 10
Study 19279381 — intervention group
Group type: COMPARATOR
Intervention: Efalizumab monotherapy
Number of subjects: 10
Study 17300358 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 378
Study 17300358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 15364353 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic complex tones and the stem frequency tone
Number of subjects: 12
Study 15364353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening stimulation
Number of subjects: 12
Study 11499329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 143